PARATEK PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 268
- Market Cap
- -
- Website
- http://www.paratekpharma.com
Study to Evaluate the PK of IV and PO Omadacycline in Children and Adolescents With Suspected or Confirmed Bacterial Infections
- Conditions
- Bacterial Infections
- Interventions
- First Posted Date
- 2022-02-01
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 40
- Registration Number
- NCT05217537
- Locations
- 🇺🇸
Site 109, Little Rock, Arkansas, United States
🇺🇸Site 112, Long Beach, California, United States
🇺🇸Site 107, Orange, California, United States
Oral Omadacycline Vs. Placebo in Adults with NTM Pulmonary Disease Caused by Mycobacterium Abscessus Complex (MABc)
- Conditions
- Mycobacterium Infections, NontuberculousNontuberculous Mycobacterial Pulmonary InfectionMycobacterium Abscessus InfectionNontuberculous Mycobacterial Lung Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-06-10
- Last Posted Date
- 2024-10-03
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 66
- Registration Number
- NCT04922554
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
🇺🇸Georgetown University Hospital, Washington, District of Columbia, United States
🇺🇸St. Francis Medical Institute, Clearwater, Florida, United States
Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia
- Conditions
- Community-acquired PneumoniaBacterial Pneumonia
- Interventions
- First Posted Date
- 2021-03-03
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 670
- Registration Number
- NCT04779242
- Locations
- 🇧🇬
Site 210, Gabrovo, Bulgaria
🇧🇬Site 213, Lom, Bulgaria
🇧🇬Site 208, Pernik, Bulgaria
Study to Evaluate the PK of PO Omadacycline in Adults With Community-Acquired Bacterial Pneumonia
- First Posted Date
- 2019-11-12
- Last Posted Date
- 2021-11-03
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 18
- Registration Number
- NCT04160260
- Locations
- 🇺🇸
Site 105, Birmingham, Alabama, United States
🇺🇸Site 102, San Diego, California, United States
🇺🇸Site 104, San Diego, California, United States
IV or IV/PO Omadacycline vs. IV/PO Levofloxacin for the Treatment of Acute Pyelonephritis
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 201
- Registration Number
- NCT03757234
- Locations
- 🇬🇪
Site 201, Tbilisi, Georgia
🇬🇪Site 202, Tbilisi, Georgia
🇬🇪Site 203, Tbilisi, Georgia
Study the Efficacy and Safety of PTK 0796 in Patients With Complicated Skin and Skin Structure Infection (CSSSI)
- Conditions
- Infectious Skin DiseaseBacterial Skin Disease
- Interventions
- First Posted Date
- 2018-10-23
- Last Posted Date
- 2020-10-12
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 234
- Registration Number
- NCT03716024
- Locations
- 🇺🇸
Paratek Recruiting Site, Wichita Falls, Texas, United States
Oral Omadacycline vs. Oral Nitrofurantoin for the Treatment of Cystitis
- Conditions
- CystitisUncomplicated Urinary Tract Infection
- Interventions
- First Posted Date
- 2018-02-07
- Last Posted Date
- 2020-06-09
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 225
- Registration Number
- NCT03425396
- Locations
- 🇺🇸
Site 106, Chula Vista, California, United States
🇺🇸Site 101, La Mesa, California, United States
🇺🇸Site 109, Los Angeles, California, United States
Oral Omadacycline vs. Oral Linezolid for the Treatment of ABSSSI
- Conditions
- Bacterial InfectionsSkin Structures and Soft Tissue Infections
- Interventions
- First Posted Date
- 2016-08-24
- Last Posted Date
- 2018-11-30
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 735
- Registration Number
- NCT02877927
- Locations
- 🇺🇸
Site 620, Birmingham, Alabama, United States
🇺🇸Site 642, Mobile, Alabama, United States
🇺🇸Site 616, Anaheim, California, United States
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
- Conditions
- Community-Acquired InfectionsBacterial Pneumonia
- Interventions
- First Posted Date
- 2015-08-24
- Last Posted Date
- 2019-01-16
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 774
- Registration Number
- NCT02531438
- Locations
- 🇺🇸
Site 514, Birmingham, Alabama, United States
🇺🇸Site 501, Mobile, Alabama, United States
🇺🇸Site 508, Laguna Hills, California, United States
Omadacycline Versus Linezolid for the Treatment of ABSSSI (EudraCT #2013-003644-23)
- Conditions
- Skin Structures and Soft Tissue InfectionsBacterial Infections
- Interventions
- First Posted Date
- 2015-03-04
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Paratek Pharmaceuticals Inc
- Target Recruit Count
- 655
- Registration Number
- NCT02378480
- Locations
- 🇺🇸
Site 261, Mobile, Alabama, United States
🇺🇸Site 262, Chula Vista, California, United States
🇺🇸Site 254, La Mesa, California, United States